��������

Stephan Emmerth has a diverse work experience in the biotech industry. Stephan started their career at Novartis - FMI, where they completed their PhD from May 2008 to June 2011. Afterwards, they worked at Swissmedic as an Associate in quality review during their civilian service from October 2011 to January 2012. Stephan then joined Roche as a Postdoc, where they conducted research on biomarkers for patients and worked on the development of Dalcetrapib from March 2012 to June 2012. Stephan also worked at Lipomed AG as a Medical and Drug Safety Expert for a brief period from July 2012 to December 2012. In 2013, they joined i-net - innovation networks as the Manager Life Sciences, providing support to entrepreneurs and companies in the implementation of their innovation and business projects until December 2015. From January 2016 to April 2018, Stephan worked at BaseLaunch as a Senior Manager in Business Development, and later as the Director of Business Development & Operations. BaseLaunch partners with scientists and entrepreneurs to launch and grow biotech companies. During their time at BaseLaunch, Stephan played a crucial role in partnering with leading organizations such as Roche, Pureos Bioventures, Johnson & Johnson Innovation, and more. In 2016, Stephan also took on a role at BaselArea.swiss as the Senior Project Manager Biotech, where they contributed to therapeutic innovation and the BaseLaunch program. In January 2019, they became the Director of Therapeutic Innovation and BaseLaunch at BaselArea.swiss, a position they currently hold. Throughout their career, Stephan has demonstrated their expertise in business development, operations, and project management in the biotech industry.

Stephan Emmerth has completed their education at the following institutions:

In 2002, they began their undergraduate studies at ETH Zürich, where they pursued a Bachelor of Science in Biology with a focus on Biochemistry and Molecular Biology. Stephan successfully completed this degree in 2006.

Following their undergraduate studies, Stephan went on to pursue advanced education at ETH Zürich. From 2006 to 2008, they attended the same institution to obtain a Master of Science in Biology, specializing in Biochemistry.

In 2016, Stephan briefly attended IE Business School to further expand their knowledge in Venture Capital through an Executive Education program.

Based on the provided information, Stephan Emmerth's education history includes a Bachelor of Science in Biology with a focus on Biochemistry and Molecular Biology from ETH Zürich, a Master of Science in Biology with a specialization in Biochemistry from the same institution, as well as an Executive Education program in Venture Capital from IE Business School.